News

Video

ARVO 2024: How mitochondria change with health in the diseased retina

At this year's ARVO meeting, Deborah A. Ferrington, PhD, presented "Genotype-specific differences in mitochondrial function specific to the CFH Y402H risk allele associated with AMD."

At this year's ARVO meeting, Deborah A. Ferrington, PhD, presented "Genotype-specific differences in mitochondrial function specific to the CFH Y402H risk allele associated with AMD."

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Deborah A. Ferrington, PhD:

Hi, my name is Deb Ferrington, and I am the Chief Scientific Officer at Doheny Eye Institute. I'll actually be speaking in a session on Thursday, and the topic of the session is focused on mitochondria and how they change with health and in the diseased retina. Mitochondria are the powerhouse of the cell, and retinal cells are very heavy in energy dependence, and so mitochondrial maintenance is critical in order for the retina to function properly. In my talk, I'm going to discuss results from a protein analysis of the retinal pigment epithelium in human donors with and without age-related macular degeneration. Our work shows that the amount and the quality of the mitochondria are significantly reduced with age-related macular degeneration, which is the number one cause of blindness among the elderly. The dramatic changes that we see in the mitochondrial proteins over the course of AMD progression indicates that this may be a good therapeutical target for treating AMD. So the next step is to dig a little deeper into what proteins are involved to see if there's really specific pathways that we could suggest targeting and perhaps working with some pharmaceutical companies to develop compounds that we could test in our cell culture system.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
© 2025 MJH Life Sciences

All rights reserved.